Renagel

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

sevelamer

Available from:

Sanofi B.V.

ATC code:

V03AE02

INN (International Name):

sevelamer

Therapeutic group:

Vsi drugi terapevtski izdelki

Therapeutic area:

Renal Dialysis; Hyperphosphatemia

Therapeutic indications:

Renagel is indicated for the control of hyperphosphataemia in adult patients receiving  haemodialysis or peritoneal dialysis. Renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.

Product summary:

Revision: 36

Authorization status:

Pooblaščeni

Authorization date:

2000-01-28

Patient Information leaflet

                                23
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Sanofi B.V.
Paasheuvelweg 25
1105 BP Amsterdam
Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET
EU/1/99/123/005
13.
ŠTEVILKA SERIJE
Številka serije
14.
NAČIN IZDAJANJA ZDRAVILA
Predpisovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Renagel
400 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC:
SN:
NN:
24
PODATKI NA ZUNANJI OVOJNINI
ZUNANJA OVOJNINA S TAKO IMENOVANIM MODRIM OKENCEM - PAKIRANJE Z VEČ
VSEBNIKI, KI VSEBUJE 720 (2 PLASTENKI S 360 TABLETAMI) TABLET PO 400
MG
ZUNANJA OVOJNINA S TAKO IMENOVANIM MODRIM OKENCEM - PAKIRANJE Z VEČ
VSEBNIKI, KI VSEBUJE 1080 (3 PLASTENKE S 360 TABLETAMI) TABLET PO 400
MG
1.
IME ZDRAVILA
Renagel 400 mg filmsko obložene tablete
sevelamerijev klorid
2.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN
Ena tableta vsebuje 400 mg sevelamerijevega klorida.
3.
SEZNAM POMOŽNIH SNOVI
4.
FARMACEVTSKA OBLIKA IN VSEBINA
Pakiranje z več vsebniki: 720 (2 plastenki s 360 tabletami) filmsko
obloženih tablet
Pakiranje z več vsebniki: 1080 (3 plastenke s 360 tabletami) filmsko
obloženih tablet
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Tablete je treba pogoltniti cele. Ne žvečite jih.
Pred uporabo preberite priloženo navodilo.
Za peroralno uporabo.
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 25
°
C.
Plastenko shranjujte tesno zaprto za zagotovitev zaščite pred vlago.
25
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Renagel 400 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena tableta vsebuje 400 mg sevelamerijevega klorida.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta (tableta)
Sivobele ovalne tablete imajo na eni strani natisnjeno oznako
„Renagel 400“.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Renagel je namenjeno uravnavanju hiperfosfatemije pri
zdravljenju odraslih bolnikov, ki
prejemajo hemodializo oziroma peritonealno dializo. Zdravilo Renagel
je treba uporabljati v smislu
večstranskega pristopa zdravljenja, ki lahko vključuje kalcijeve
dodatke, 1,25 – dihidroksi vitamin D
3
ali kakšen njegov analog, za nadziranje razvoja renalne
osteodistrofije.
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
_Začetni odmerek_
Priporočen začetni odmerek sevelamerijevega klorida
je 2,4 g, 3,6 g ali 4,8 g na dan glede na klinične
potrebe in ravni serumskega fosforja. Zdravilo Renagel je treba jemati
trikrat na dan z obroki.
Raven fosfata v serumu pri bolnikih,
ki ne jemljejo fosfatnih vezalcev
Začetni odmerek zdravila
Renagel 400 mg tablete
1,76 – 2,42 mmol/l (5,5 - 7,5 mg/dl)
3-krat na dan po 2 tableti
2,42 – 2,91 mmol/l (7,5 – 9 mg/dl)
3-krat na dan po 3 tablete
> 2,91 mmol/l
3-krat na dan po 4 tablete
Bolnikom, ki so prej jemali vezalce fosfata, je treba zdravilo Renagel
dajati na osnovi gram po gram
ter pri tem nadzirati ravni fosforja v serumu, da se zagotovijo
optimalni dnevni odmerki.
_Titriranje in vzdrževanje _
Koncentracijo fosfata v serumu je treba skrbno spremljati in odmerek
sevelamerijevega klorida titrirati
z 0,4 do 0,8 g odmerkom trikrat na dan (1,2 g/dan ali 2,4 g/dan) glede
na cilj znižanja fosfata v serumu
na 1,76 mmol/l (5,5 mg/dl) ali manj. Fosfat v serumu je treba
preverjati vsake dva do tri tedne, dokler
ni dosežena stabilna koncentracija fosfata v serumu, in potem redno.
Odmerek je lahko od 1 do 10 tablet pri enem obroku. Povprečni d
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 07-08-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 07-08-2023
Public Assessment Report Public Assessment Report Bulgarian 13-07-2015
Patient Information leaflet Patient Information leaflet Spanish 07-08-2023
Public Assessment Report Public Assessment Report Spanish 13-07-2015
Patient Information leaflet Patient Information leaflet Czech 07-08-2023
Public Assessment Report Public Assessment Report Czech 13-07-2015
Patient Information leaflet Patient Information leaflet Danish 07-08-2023
Public Assessment Report Public Assessment Report Danish 13-07-2015
Patient Information leaflet Patient Information leaflet German 07-08-2023
Public Assessment Report Public Assessment Report German 13-07-2015
Patient Information leaflet Patient Information leaflet Estonian 07-08-2023
Public Assessment Report Public Assessment Report Estonian 13-07-2015
Patient Information leaflet Patient Information leaflet Greek 07-08-2023
Public Assessment Report Public Assessment Report Greek 13-07-2015
Patient Information leaflet Patient Information leaflet English 07-08-2023
Public Assessment Report Public Assessment Report English 13-07-2015
Patient Information leaflet Patient Information leaflet French 07-08-2023
Public Assessment Report Public Assessment Report French 13-07-2015
Patient Information leaflet Patient Information leaflet Italian 07-08-2023
Public Assessment Report Public Assessment Report Italian 13-07-2015
Patient Information leaflet Patient Information leaflet Latvian 07-08-2023
Public Assessment Report Public Assessment Report Latvian 13-07-2015
Patient Information leaflet Patient Information leaflet Lithuanian 07-08-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 07-08-2023
Public Assessment Report Public Assessment Report Lithuanian 13-07-2015
Patient Information leaflet Patient Information leaflet Hungarian 07-08-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 07-08-2023
Public Assessment Report Public Assessment Report Hungarian 13-07-2015
Patient Information leaflet Patient Information leaflet Maltese 07-08-2023
Public Assessment Report Public Assessment Report Maltese 13-07-2015
Patient Information leaflet Patient Information leaflet Dutch 07-08-2023
Public Assessment Report Public Assessment Report Dutch 13-07-2015
Patient Information leaflet Patient Information leaflet Polish 07-08-2023
Public Assessment Report Public Assessment Report Polish 13-07-2015
Patient Information leaflet Patient Information leaflet Portuguese 07-08-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 07-08-2023
Public Assessment Report Public Assessment Report Portuguese 13-07-2015
Patient Information leaflet Patient Information leaflet Romanian 07-08-2023
Public Assessment Report Public Assessment Report Romanian 13-07-2015
Patient Information leaflet Patient Information leaflet Slovak 07-08-2023
Public Assessment Report Public Assessment Report Slovak 13-07-2015
Patient Information leaflet Patient Information leaflet Finnish 07-08-2023
Public Assessment Report Public Assessment Report Finnish 13-07-2015
Patient Information leaflet Patient Information leaflet Swedish 07-08-2023
Public Assessment Report Public Assessment Report Swedish 13-07-2015
Patient Information leaflet Patient Information leaflet Norwegian 07-08-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 07-08-2023
Patient Information leaflet Patient Information leaflet Icelandic 07-08-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 07-08-2023
Patient Information leaflet Patient Information leaflet Croatian 07-08-2023
Public Assessment Report Public Assessment Report Croatian 13-07-2015

Search alerts related to this product

View documents history